스피로놀락톤 관련 여성형 탈모증

References

1. [1] Abhijeet Kumar Jha et al.. Clin Exp Dermatol. 2026. Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial. doi:10.1093/ced/llag099 PubMed
2. [2] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
3. [3] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
4. [4] Juan Jimenez-Cauhe et al.. J Am Acad Dermatol. 2025. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. doi:10.1016/j.jaad.2024.12.048 PubMed
5. [5] Pimpakarn Werachattawatchai et al.. Int J Womens Dermatol. 2025. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … doi:10.1097/JW9.0000000000000227 PubMed
6. [6] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
7. [7] Naglaa Mohamad Al Sayed et al.. Dermatol Pract Concept. 2025. Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. doi:10.5826/dpc.1501a4698 PubMed
8. [8] Ghada Fawzy Rezk Hassan et al.. Int J Trichology. 2025. Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: … doi:10.4103/ijt.ijt_118_23 PubMed
9. [9] Sasithorn Limsuwan et al.. Front Vet Sci. 2024. Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs. doi:10.3389/fvets.2024.1389810 PubMed
10. [10] Afsaneh Sadeghzadeh Bazargan et al.. J Cosmet Dermatol. 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … doi:10.1111/jocd.15979 PubMed
11. [11] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
12. [12] Abhijeet Kumar Jha et al.. Australas J Dermatol. 2024. Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study. doi:10.1111/ajd.14306 PubMed
13. [13] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
14. [14] Laura E Ewing et al.. Food Chem Toxicol. 2024. Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice. doi:10.1016/j.fct.2024.114909 PubMed
15. [15] Ambika Nohria et al.. JAAD Int. 2024. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … doi:10.1016/j.jdin.2024.07.023 PubMed
16. [16] Majed Aleissa. Cureus. 2023. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. doi:10.7759/cureus.43559 PubMed
17. [17] Shreya Deoghare et al.. J Cosmet Laser Ther. 2023. Combination therapy in female pattern hair loss. doi:10.1080/14764172.2023.2222942 PubMed
18. [18] Marko Kumric et al.. J Pers Med. 2022. Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension … doi:10.3390/jpm12071037 PubMed
19. [19] Xuelei Liang et al.. Front Med (Lausanne). 2022. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … doi:10.3389/fmed.2022.905140 PubMed
20. [20] Pravesh Sharma et al.. PEC Innov. 2022. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … doi:10.1016/j.pecinn.2022.100044 PubMed
21. [21] Laura J Burns et al.. J Am Acad Dermatol. 2020. Spironolactone for treatment of female pattern hair loss. doi:10.1016/j.jaad.2020.03.087 PubMed
22. [22] T N Searle et al.. Clin Exp Dermatol. 2020. Spironolactone in dermatology: uses in acne and beyond. doi:10.1111/ced.14340 PubMed
23. [23] Alfredo Rossi et al.. Dermatol Pract Concept. 2020. Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind … doi:10.5826/dpc.1002a39 PubMed
24. [24] Enrico Carmina et al.. J Clin Endocrinol Metab. 2019. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. doi:10.1210/jc.2018-02548 PubMed
25. [25] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
26. [26] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
27. [27] Raquel N Rozner et al.. Breast Cancer Res Treat. 2019. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. doi:10.1007/s10549-018-4996-3 PubMed
28. [28] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
29. [29] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
30. [30] G Fabbrocini et al.. Int J Womens Dermatol. 2018. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. doi:10.1016/j.ijwd.2018.05.001 PubMed
31. [31] Linda Chan et al.. Aust J Gen Pract. 2018. Female pattern hair loss. doi:10.31128/AJGP-02-18-4498 PubMed
32. [32] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
33. [33] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
34. [34] Timothy H Schmidt et al.. J Am Acad Dermatol. 2015. Evidence-based approach to cutaneous hyperandrogenism in women. doi:10.1016/j.jaad.2015.05.026 PubMed
35. [35] Shannon Famenini et al.. J Am Acad Dermatol. 2015. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. doi:10.1016/j.jaad.2015.06.063 PubMed
36. [36] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
37. [37] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
38. [38] C M Salavastru et al.. Hautarzt. 2013. [Spironolactone in dermatological treatment. On and off label indications]. doi:10.1007/s00105-013-2597-y PubMed
39. [39] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
40. [40] R Sinclair et al.. Br J Dermatol. 2011. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. doi:10.1111/j.1365-2133.2011.10630.x PubMed
41. [41] Anosha Yazdabadi et al.. Australas J Dermatol. 2011. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. doi:10.1111/j.1440-0960.2010.00735.x PubMed
42. [42] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
43. [43] Deepani Rathnayake et al.. Skinmed. 2010. Use of spironolactone in dermatology. PubMed
44. [44] Anosha Yazdabadi et al.. Australas J Dermatol. 2009. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. doi:10.1111/j.1440-0960.2009.00517.x PubMed
45. [45] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
46. [46] . Harv Womens Health Watch. 2009. Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help. PubMed
47. [47] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
48. [48] Carlijn Hoedemaker et al.. Australas J Dermatol. 2007. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. doi:10.1111/j.1440-0960.2007.00332.x PubMed
49. [49] Matti Hannuksela. Duodecim. 2006. [The treatment of female pattern hair loss]. PubMed
50. [50] Elise A Olsen et al.. J Am Acad Dermatol. 2005. Evaluation and treatment of male and female pattern hair loss. doi:10.1016/j.jaad.2004.04.008 PubMed
51. [51] R Sinclair et al.. Br J Dermatol. 2005. Treatment of female pattern hair loss with oral antiandrogens. doi:10.1111/j.1365-2133.2005.06218.x PubMed
52. [52] Rodney Sinclair. J Am Acad Dermatol. 2005. Chronic telogen effluvium: a study of 5 patients over 7 years. doi:10.1016/j.jaad.2004.05.040 PubMed